"Authorized" Generics' Short-Term Benefits Outweighed By Drag On ANDAs, GPhA Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Although authorized generics may stimulate competition, they undermine the incentive to submit generic drug applications, GPhA maintains. Association will "keep our options open" in determining "next steps."
You may also be interested in...
FDA Signs Off On "Authorized" Generics; Deals Are Pro-Competitive, Agency Says
FDA is not empowered to directly regulate the timing for marketing of previously approved drug products, the agency says in response to citizen petitions from Mylan and Teva. The two companies wanted FDA to prohibit the marketing of authorized generics during a first ANDA filer's 180-day exclusivity period.
Mylan Demands FDA Response On “Authorized” Generics By July 6
A supplement to Mylan’s citizen petition requests that FDA act immediately to bar authorized generics. Mylan asserts there is no evidence suggesting that authorized generics benefit consumers.
"Authorized" Generics Reduce The Incentive For Patent Challenges, GPhA Says
"Authorized" generics reduce the incentive for generic manufacturers to challenge questionable pharmaceutical patents, the Generic Pharmaceutical Association says